ASCO GUIDELINES Bundle

Metastatic HER2-Negative Breast Cancer – Chemo and Targeted Therapy Either Endocrine-Pretreated or Hormone Receptor-Negative

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/1475478

Contents of this Issue

Navigation

Page 0 of 7

Metastatic HER2- Negative Breast Cancer – Chemo- and Targeted Therapy Either Endocrine-Pretreated or Hormone Receptor-Negative Adapted from: Moy B, et al. J Clin Oncol. 2022 August 04. doi: 10.1200/JCO.22.01533 Moy B, et al. J Clin Oncol. 2021 July 29. doi: 10.1200/JCO.21.01374 Introduction Treatment

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Metastatic HER2-Negative Breast Cancer – Chemo and Targeted Therapy Either Endocrine-Pretreated or Hormone Receptor-Negative